Skip to main content

Melphalan Approved for Liver-Directed Treatment for Uveal Melanoma

The FDA has approved melphalan for injection (Hepzato Kit™/Hepatic Delivery System), containing melphalan (Hepzato™, Delcath Systems, Inc.) as a liver-directed treatment for patients with uveal melanoma with unresectable hepatic metastases affecting ≤50% of the liver. This treatment is permitted for those with no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. This application was granted or...

Continue reading